GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

HRS-5346 is an investigational oral small molecule inhibitor of Lipoprotein (a) formation, that might result in atherosclerotic cardiovascular disease. HRS-5346 is currently in a Phase 2 clinical ...

Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several ...

We believe Merck’s clinical expertise and global scale will help accelerate the development of HRS-5346 and potentially provide more patients with an additional option to reduce their risk of ...

BioWorld Content on 'HRS-5346'For nearly $2B, Jiangsu Hengrui licenses heart drug to Merck March 25, 2025 By Lee Landenberger ...

Merck on Tuesday said it will make an upfront payment of $200 million to Hengrui Pharma to license HRS-5346, which is currently in a Phase 2 study in China for the reduction of lipoprotein (a), or ...

Under the latest deal, announced on Tuesday, Merck will get exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals' experimental oral heart disease drug, HRS-5346 ...

The company will also be required to pay royalties on net sales of HRS-5346 subject to the drug’s regulatory clearance. GSK wins approval of antibiotic gepotidacin for urinary tract infections ...